Morie Gertz, MD
Enriched profileRoland Seidler Jr. Professor of the Art of Medicine; Chair Emeritus, Department of Internal Medicine, Mayo Clinic (transitioned from active Chair sometime between Dec 2023 and July 2024 -- see qa_log) · Mayo Clinic in Rochester
Morie Gertz is Roland Seidler Jr. Professor of the Art of Medicine; Chair Emeritus, Department of Internal Medicine, Mayo Clinic (transitioned from active Chair sometime between Dec 2023 and July 2024 -- see qa_log) at Mayo Clinic in Rochester. OpenAlex indexes 1,944 publications with 84,365 citations (h-index 140); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Morie Gertz, M.D., is Roland Seidler Jr. Professor of the Art of Medicine at Mayo Clinic in Rochester, Minnesota. The public record shows 1,944 publications with 84,365 citations (h-index 140), centered on Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 15 companies, 1 NIH-funded awards (2005–2011).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 218 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 817.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Sponsor: National Cancer Institute (NCI)
- Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Sponsor: Eastern Cooperative Oncology Group
Industry payments
Updated 27 Aug 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year202515 payments$17,622openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20252 payments
- Hexal AGProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
75.3%SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor68.8%Remdesivir100%Part B, office-administered≥11 patientsShort-acting sulfonamides3%Sulfamethoxazole-Trimethoprim100%Part D≥26 patientsCancer & immunology
8.8%Thalidomide Analog8.8%Revlimid42%Lenalidomide32%Pomalyst26%Part D≥24 patientsDermatology
5.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5.9%Acyclovir100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2005–2011 per NIH RePORTER. The latest:
- Phase 3 stem cell transplant for light chain amyloidosis
Mayo Clinic Rochester
FY2011$163,055R01CA111345 - Phase 3 stem cell transplant for light chain amyloidosis
Mayo Clinic Rochester
FY2010$267,768R01CA111345 - Phase 3 stem cell transplant for light chain amyloidosis
Mayo Clinic Rochester
FY2009$301,913R01CA111345
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.
American journal of hematology
Article2026 - Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.
British journal of haematology
Article2026 - Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
American journal of hematology
Article2026
Most-cited works
by citation count (OpenAlex)- 01International uniform response criteria for multiple myeloma2,640 citations2006
- 02Review of 1027 Patients With Newly Diagnosed Multiple Myeloma2,432 citations2003
- 03Improved survival in multiple myeloma and the impact of novel therapies2,252 citations2007
- 04
- 05Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis1,423 citations2018
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/morie-gertz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/morie-gertz-b880b73a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Morie-Gertz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/C1XLgCGu8cs
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
healthtree.org/myeloma/community/podcasts/july2024-podcast-amyloidosis-morie-gertz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - Other
bloodcancerstoday.com/podcast/morie-gertz-md-on-clinical-trials-and-controversies-in-smoldering-mm
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Hematology and Medical Oncology, Mayo Clinic College of Medicine and Science (Rochester), 1979-1983
1983verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Residency
Internal Medicine, Rush Presbyterian-St. Luke's Medical Center / Rush University Medical Center, Chicago, 1976-1979 (voted Resident of the Year, 2 years)
1979verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - MD
Loyola University Chicago Stritch School of Medicine (Maywood, IL), cum laude, elected Alpha Omega Alpha
1975verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
- Former Chair
Division of Hematology, Mayo Clinic
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Awards & honors
honors on the public record- 2019 Research Career Achievement Award / Lifetime Research Achievement Award
Department of Medicine, Mayo Clinic
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.abim.org ↗
Secondary affiliations
appointments beyond the home institution- Member
Scientific Advisory Board, Attralus, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →attralus.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- Morie Gertz
MD, on Clinical Trials and Controversies in Smoldering MM (Blood Cancers Today podcast)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sean Pittock, MD
Mayo Clinic in Rochester
Adrian Vella, MD
Mayo Clinic in Rochester
Benjamin Hibbert, MD
Mayo Clinic in Rochester